Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of malignant plasma cells in bone marrow, bone lesions, renal failure and immunodeficiency. MM is responsible for ∼1% of all cancers and ∼2% of cancer deaths. Both biologically based and immune based therapies offer significant opportunities for improved patient outcome. However, despite recent advances in treatment, multiple myeloma remains an incurable disease. Accordingly it is recognized that improved knowledge of novel, as-yet unidentified, molecules or pathways that improve our understanding of the development of malignant clones of plasma cells will foster development of new therapies.
Citation: Kotwica K, Cioch MB, Dmoszynska A (2011) Expression of Surface Molecules on Multiple Myeloma Cells and their Potential Role in Pathogenesis, Prognosis, and Treatment. J Mol Biomark Diagn 2:103.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi